MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Up 23.0% in April

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 2,834,997 shares, a growth of 23.0% from the March 31st total of 2,304,530 shares. Approximately 5.8% of the shares of the company are short sold. Based on an average daily volume of 698,485 shares, the days-to-cover ratio is presently 4.1 days.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently modified their holdings of MAIA. Jane Street Group LLC acquired a new stake in shares of MAIA Biotechnology in the 4th quarter worth about $120,000. Geode Capital Management LLC grew its position in MAIA Biotechnology by 9.5% in the 4th quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after purchasing an additional 25,684 shares during the last quarter. Centric Wealth Management grew its position in MAIA Biotechnology by 2.0% in the 4th quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after purchasing an additional 11,500 shares during the last quarter. Ritholtz Wealth Management acquired a new stake in shares of MAIA Biotechnology in the fourth quarter valued at approximately $35,000. Finally, Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology during the second quarter valued at approximately $29,000. Institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Stock Performance

Shares of MAIA Biotechnology stock traded up $0.01 on Friday, reaching $1.34. 580,779 shares of the company were exchanged, compared to its average volume of 661,763. The firm has a market cap of $81.30 million, a price-to-earnings ratio of -1.94 and a beta of 0.21. MAIA Biotechnology has a 1-year low of $0.87 and a 1-year high of $3.19. The company’s 50-day moving average is $1.51 and its two-hundred day moving average is $1.52.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Monday, March 23rd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. As a group, sell-side analysts forecast that MAIA Biotechnology will post -0.69 earnings per share for the current year.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.